Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: A case report

被引:6
|
作者
Shimabukuro-Vornhagen A. [1 ]
Rothe A. [1 ]
Nogova L. [1 ]
Kochanek M. [1 ]
Scheid C. [1 ]
Von Bergwelt-Baildon M. [1 ]
机构
[1] Department i of Internal Medicine, University Hospital Cologne, D-50924 Köln
关键词
Imatinib; Chronic Myeloid Leukemia; International Normalize Ratio; Dasatinib; Fresh Freeze Plasma;
D O I
10.1186/1752-1947-5-215
中图分类号
学科分类号
摘要
Introduction. In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL+ clone and often induce complete molecular remissions. Megakaryocytes in such patients have been shown to be derived from the BCR-ABL+ clone, and abnormal platelet function is frequent in chronic myeloid leukemia. However, little is known about the influence of modern targeted therapy on chronic myeloid leukemia-associated platelet disorders. Case presentation. We report the case of a massive hemorrhage in a 32-year-old Caucasian man caused by chronic myeloid leukemia-associated platelet dysfunction, which improved after treatment with imatinib. Conclusion: This report demonstrates that platelet dysfunction and bleeding disorder in BCR-ABL+ chronic myeloid leukemia can successfully be treated with imatinib. We suggest the monitoring of platelet function in future studies using imatinib to treat patients with chronic myeloid leukemia. © 2011 Shimabukuro-Vornhagen et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [21] Periungual Pyogenic Granuloma Following Imatinib Therapy in a Patient With Chronic Myelogenous Leukemia
    Dika, Emi
    Barisani, Alessia
    Vaccari, Sabina
    Fanti, Pier Alessandro
    Ismaili, Alma
    Patrizi, Annalisa
    JOURNAL OF DRUGS IN DERMATOLOGY, 2013, 12 (05) : 512 - 513
  • [22] Chronic myelogenous leukemia following small lymphocytic lymphoma: a case report and review of literature
    Gong, Xubo
    Lv, Minfang
    Yu, Teng
    Xiao, Xibin
    Yan, Lijuan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (10): : 5133 - 5138
  • [23] An analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations
    Paquin, Dana
    Sacco, David
    Shamshoian, John
    MATHEMATICAL BIOSCIENCES, 2015, 262 : 117 - 124
  • [24] THYMOMA AND CHRONIC MYELOGENOUS LEUKEMIA - CASE-REPORT
    KNOWLES, DM
    CANCER, 1976, 38 (03) : 1414 - 1419
  • [25] CHRONIC MYELOGENOUS LEUKEMIA AND GLOMERULONEPHRITIS - REPORT OF A NEW CASE
    GAGO, ES
    LUNO, E
    QUINONES, L
    JONTE, F
    ALVAREZ, J
    AMERICAN JOURNAL OF MEDICINE, 1986, 81 (06): : 1121 - 1122
  • [26] Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
    Kimura, Shun-ichi
    Kako, Shinichi
    Wada, Hidenori
    Sakamoto, Kana
    Ashizawa, Masahiro
    Sato, Mild
    Terasako, Kiriko
    Kikuchi, Misato
    Nakasone, Hideki
    Okuda, Shinya
    Yamazaki, Rie
    Oshima, Kumi
    Nishida, Junji
    Watanabe, Takuro
    Kanda, Yoshinobu
    LEUKEMIA RESEARCH, 2011, 35 (01) : E11 - E12
  • [27] Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia
    Lokeshwar, N
    Kumar, L
    Kumari, M
    LEUKEMIA & LYMPHOMA, 2005, 46 (05) : 781 - 784
  • [28] Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
    Akay, Olga Meltem
    Mutlu, Fezan
    Gulbas, Zafer
    TURKISH JOURNAL OF HEMATOLOGY, 2016, 33 (02) : 127 - 130
  • [29] Response of concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia to imatinib mesylate
    Yoon, Ju-Yoon
    Kumar, Rajat
    Aloyz, Raquel
    Johnston, James B.
    LEUKEMIA RESEARCH, 2011, 35 (09) : E179 - E180
  • [30] Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
    Chu, Su
    McDonald, Tinisha
    Lin, Allen
    Chakraborty, Sujata
    Huang, Qin
    Snyder, David S.
    Bhatia, Ravi
    BLOOD, 2011, 118 (20) : 5565 - 5572